AR067119A1 - Material particulado de un antagonista de crth2 - Google Patents
Material particulado de un antagonista de crth2Info
- Publication number
- AR067119A1 AR067119A1 ARP080102676A ARP080102676A AR067119A1 AR 067119 A1 AR067119 A1 AR 067119A1 AR P080102676 A ARP080102676 A AR P080102676A AR P080102676 A ARP080102676 A AR P080102676A AR 067119 A1 AR067119 A1 AR 067119A1
- Authority
- AR
- Argentina
- Prior art keywords
- micrometers
- particulate material
- crth2 antagonist
- crth2
- particulated material
- Prior art date
Links
- 229940124003 CRTH2 antagonist Drugs 0.000 title 1
- 239000000463 material Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000011236 particulate material Substances 0.000 abstract 2
- XEOSTBFUCNZKGS-UHFFFAOYSA-N 2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=CC(=CC=3)C(F)(F)F)=CC=2)=N1 XEOSTBFUCNZKGS-UHFFFAOYSA-N 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos utiles, procesos para su preparacion, y composiciones farmacéuticas para el tratamiento, la prevencion o el alivio de uno o más síntomas de un trastorno o una enfermedad mediada por CRTH2, tales como rinitis alérgica, asma, broncoconstriccion, dermatitis atopica o trastornos inflamatorios sistémicos. Reivindicacion 1: Material particulado del ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)-bencil)pirimidin-5-il} acético de la formula 1: en la forma 1 cristalina; en donde el material particulado tiene un tamano promedio de partícula que varía de alrededor de 0,1 a alrededor de 150 micrometros, de alrededor de 0,5 a alrededor de 100 micrometros, de alrededor de 1 a alrededor de 50 micrometros, de alrededor de 1 a alrededor de 25 micrometros, de alrededor de 1 a alrededor de 20 micrometros, de alrededor de 1 a alrededor de 10 micrometros, de alrededor de 2 a alrededor de 10 micrometros, o de alrededor de 2 a alrededor de 7,5 micrometros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93697207P | 2007-06-21 | 2007-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067119A1 true AR067119A1 (es) | 2009-09-30 |
Family
ID=39708813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102676A AR067119A1 (es) | 2007-06-21 | 2008-06-20 | Material particulado de un antagonista de crth2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8507005B2 (es) |
| EP (1) | EP2170838A1 (es) |
| JP (1) | JP2010530425A (es) |
| KR (1) | KR20100023046A (es) |
| CN (3) | CN103172572A (es) |
| AR (1) | AR067119A1 (es) |
| AU (1) | AU2008266853A1 (es) |
| BR (1) | BRPI0813436A2 (es) |
| CA (1) | CA2690172A1 (es) |
| CL (1) | CL2008001818A1 (es) |
| CO (1) | CO6290713A2 (es) |
| EC (1) | ECSP109890A (es) |
| IL (1) | IL202679A0 (es) |
| MA (1) | MA31534B1 (es) |
| NZ (1) | NZ581811A (es) |
| RU (1) | RU2468012C2 (es) |
| TN (1) | TN2009000518A1 (es) |
| TW (1) | TW200911762A (es) |
| UA (1) | UA99138C2 (es) |
| WO (1) | WO2008156780A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1471057E (pt) | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| NZ581856A (en) * | 2007-06-21 | 2011-05-27 | Actimis Pharmaceuticals Inc | Amine salts of the CRTH2 antagonist {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid |
| US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| WO2010008864A2 (en) | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2011005645A1 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Polymorph of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] |
| WO2011014587A2 (en) | 2009-07-31 | 2011-02-03 | Amira Pharmaceuticals, Inc. | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| KR20120047273A (ko) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| WO2011066147A2 (en) | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Novel salt forms of pyrimidin-5-yl acetic acid derivative |
| EP2504319A1 (en) | 2009-11-24 | 2012-10-03 | Boehringer Ingelheim International GmbH | Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| CN110740724A (zh) * | 2017-06-12 | 2020-01-31 | 诺华股份有限公司 | 无定形的纳米结构药物材料 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078690B2 (en) * | 2002-02-04 | 2006-07-18 | Applied Materials, Israel, Ltd. | Monitoring of contact hole production |
| PT1471057E (pt) * | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| ATE433452T1 (de) * | 2004-01-31 | 2009-06-15 | Actimis Pharmaceuticals Inc | Imidazoä1,2-cüpyrimidinylessigsäurederivate |
-
2008
- 2008-06-18 WO PCT/US2008/007589 patent/WO2008156780A1/en not_active Ceased
- 2008-06-18 BR BRPI0813436-7A2A patent/BRPI0813436A2/pt not_active IP Right Cessation
- 2008-06-18 NZ NZ581811A patent/NZ581811A/xx not_active IP Right Cessation
- 2008-06-18 UA UAA201000542A patent/UA99138C2/ru unknown
- 2008-06-18 CN CN2013100434078A patent/CN103172572A/zh active Pending
- 2008-06-18 RU RU2010101804/04A patent/RU2468012C2/ru not_active IP Right Cessation
- 2008-06-18 EP EP08768582A patent/EP2170838A1/en not_active Withdrawn
- 2008-06-18 CA CA2690172A patent/CA2690172A1/en not_active Abandoned
- 2008-06-18 CN CN2008801032394A patent/CN101778830B/zh not_active Expired - Fee Related
- 2008-06-18 CN CN2013100434631A patent/CN103172573A/zh active Pending
- 2008-06-18 JP JP2010513234A patent/JP2010530425A/ja active Pending
- 2008-06-18 AU AU2008266853A patent/AU2008266853A1/en not_active Abandoned
- 2008-06-18 US US12/665,706 patent/US8507005B2/en not_active Expired - Fee Related
- 2008-06-18 KR KR1020107001462A patent/KR20100023046A/ko not_active Ceased
- 2008-06-19 CL CL2008001818A patent/CL2008001818A1/es unknown
- 2008-06-20 TW TW097123253A patent/TW200911762A/zh unknown
- 2008-06-20 AR ARP080102676A patent/AR067119A1/es not_active Application Discontinuation
-
2009
- 2009-12-10 IL IL202679A patent/IL202679A0/en unknown
- 2009-12-10 TN TNP2009000518A patent/TN2009000518A1/fr unknown
-
2010
- 2010-01-19 MA MA32538A patent/MA31534B1/fr unknown
- 2010-01-20 CO CO10005024A patent/CO6290713A2/es not_active Application Discontinuation
- 2010-01-21 EC EC2010009890A patent/ECSP109890A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ581811A (en) | 2012-11-30 |
| KR20100023046A (ko) | 2010-03-03 |
| MA31534B1 (fr) | 2010-07-01 |
| US20110052701A1 (en) | 2011-03-03 |
| HK1144939A1 (en) | 2011-03-18 |
| ECSP109890A (es) | 2010-03-31 |
| TW200911762A (en) | 2009-03-16 |
| WO2008156780A1 (en) | 2008-12-24 |
| EP2170838A1 (en) | 2010-04-07 |
| JP2010530425A (ja) | 2010-09-09 |
| BRPI0813436A2 (pt) | 2014-12-23 |
| CN101778830A (zh) | 2010-07-14 |
| CN101778830B (zh) | 2013-03-20 |
| AU2008266853A1 (en) | 2008-12-24 |
| TN2009000518A1 (en) | 2011-03-31 |
| CN103172573A (zh) | 2013-06-26 |
| CL2008001818A1 (es) | 2009-03-06 |
| IL202679A0 (en) | 2010-06-30 |
| UA99138C2 (ru) | 2012-07-25 |
| US8507005B2 (en) | 2013-08-13 |
| RU2468012C2 (ru) | 2012-11-27 |
| CO6290713A2 (es) | 2011-06-20 |
| CA2690172A1 (en) | 2008-12-24 |
| CN103172572A (zh) | 2013-06-26 |
| RU2010101804A (ru) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067119A1 (es) | Material particulado de un antagonista de crth2 | |
| MY157429A (en) | Trpm8 antagonists and their use in treatments | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| UY31526A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| CL2016002888A1 (es) | Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras. | |
| CL2013002194A1 (es) | Compuestos derivados de 1-(1-(quinazolin-2-il) o quinolin-2-il)metil-piperidina, 1-(naftalen-2-il)metil)-(piperidina o perhidro-azepina) y otros derivados de los mismos; su composicion farmaceutica; y uso como moduladores de la actividad de los receptores de s1p, en el tratamiento de esclerosis multiple, enfermedades autoinmunes, trastornos inflamatorios cronicos, asma, artritis, entre otras. | |
| WO2007146838A3 (en) | Substituted phenyl acetic acids as dp-2 antagonists | |
| UY29167A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| CL2011002197A1 (es) | Compuestos derivados de piperidinas sustituidas; composición farmacéutica que los comprende; y su uso como inhibidores de los receptores ccr3 para la prevención y/o el tratamiento de enfermedades tales como asma, alergias, epoc, artritis reumatoide y aterosclerosis. | |
| BR112015009913A2 (pt) | composições farmacêuticas para o tratamento de doenças mediadas por cftr | |
| HK1199259A1 (en) | Lysophosphatidic acid receptor antagonists | |
| CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
| CL2013003333A1 (es) | Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras. | |
| CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| CL2012002570A1 (es) | Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios. | |
| ECSP099087A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| WO2008152093A3 (en) | Diaminopyrimidines as modulators of the ep2 receptor | |
| NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| BR112012028763A2 (pt) | heteroaril-cicloexil-tetra-azatetra-azabenzeno[e]azulenos | |
| WO2007143745A3 (en) | Substituted phenyl acetic acids as dp-2 antagonists | |
| PA8808201A1 (es) | Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi | |
| JO3458B1 (ar) | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 | |
| WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses | |
| NZ601155A (en) | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |